Understanding how tumor cells evade the immune system through specific pathways
Elucidating the role of tumor cell-intrinsic hypoxia inducible factor (HIF)-1α and HIF-2α pathway activation in tumor immune evasion
This study is looking at how certain factors in tumor cells help them hide from the immune system, which could help us find better ways to make cancer treatments work more effectively for patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Chicago NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-11087543 on NIH RePORTER |
What this research studies
This research investigates how certain pathways within tumor cells, specifically the hypoxia-inducible factors HIF-1α and HIF-2α, contribute to the ability of tumors to evade the immune system. By examining the tumor microenvironment and its effects on T cell responses, the study aims to uncover mechanisms that lead to resistance against immunotherapy treatments. Patients may benefit from this research as it could lead to improved strategies for enhancing the effectiveness of immunotherapies in cancer treatment.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that are currently treated with immunotherapy but are not responding effectively.
Not a fit: Patients with cancers that do not involve immune checkpoint inhibitors or those who are not candidates for immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for cancer patients.
How similar studies have performed: Other research has shown promising results in understanding tumor immune evasion, but the specific focus on HIF-1α and HIF-2α pathways in this context is relatively novel.
Where this research is happening
Chicago, United States
- University of Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Trujillo, Jonathan a — University of Chicago
- Study coordinator: Trujillo, Jonathan a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.